Skip to main content

Advertisement

Table 1 Baseline demographic and disease characteristics

From: Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

  Pooled, PBO-controlled studies [16] ABPM study [17]
Characteristica PBO (n = 646) CANA 100 mg (n = 833) CANA 300 mg (n = 834) PBO (n = 56) CANA 100 mg (n = 57) CANA 300 mg (n = 56)
Sex, n (%)
 Male 334 (52) 408 (49) 404 (48) 33 (59) 34 (60) 31 (55)
 Female 312 (48) 425 (51) 430 (52) 23 (41) 23 (40) 25 (45)
Age, years 56.3 (9.8) 55.9 (10.1) 55.7 (9.5) 59.6 (9.5) 57.8 (8.7) 58.3 (6.9)
Race, n (%)b
 White 470 (73) 591 (71) 610 (73) 46 (82) 45 (79) 43 (77)
 Black or African American 28 (4) 43 (5) 48 (6) 9 (16) 10 (18) 12 (21)
 Asian 82 (13) 103 (12) 100 (12) 0 1 (2) 1 (2)
 Otherc 66 (10) 96 (12) 76 (9) 1 (2) 1 (2) 0
HbA1c,  % 8.0 (0.9) 8.0 (0.9) 8.0 (1.0) 8.2 (0.9) 8.1 (0.9) 8.0 (0.8)
BMI, kg/m2 31.9 (6.4) 32.3 (6.4) 32.0 (6.5) 32.9 (5.7) 33.0 (6.0) 34.1 (6.8)
eGFR, mL/min/1.73 m2 87.0 (19.8) 88.3 (19.0) 88.8 (18.9) 87.9 (18.3) 87.2 (20.3) 85.6 (19.7)
Duration of T2DM, years 7.5 (6.2) 7.2 (5.8) 7.4 (6.2) 11.8 (8.7) 9.4 (6.0) 10.3 (6.2)
Seated SBP, mmHg 128.5 (13.2) 128.0 (12.8) 128.8 (12.8) 137.7 (8.6) 138.5 (11.1) 139.2 (8.8)
Seated DBP, mmHg 77.9 (8.3) 77.5 (8.0) 78.2 (8.3) 82.7 (8.6) 82.4 (7.7) 83.0 (8.2)
  1. ABPM ambulatory blood pressure monitoring, BMI body mass index, CANA canagliflozin, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, PBO placebo, SD standard deviation, SBP systolic blood pressure, T2DM type 2 diabetes mellitus
  2. aData are mean (SD) unless otherwise indicated
  3. bPercentages may not total 100% due to rounding
  4. cIncludes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other, unknown, and not reported in the pooled, PBO-controlled studies; and includes other and unknown in the ABPM study